[Clinical significance of cevimeline hydrochloride in the treatment of dry mouth in patients with Sjögren's syndrome].
To evaluate the efficacy and safety of cevimeline hydrochloride for the treatment of dry mouth in patients with Sjögren's syndrome (SS), eight SS patients received 30 mg of cevimeline twice or three times daily for 24 weeks. Six out of the eight patients had improvement in dry mouth. Five patients had more than 20% increase in saliva secretion. In the assessment of salivary gland scintigraphy, three patients showed improvement. There was a significant negative correlation between the improvement of saliva secretion and the severity of tissue damage assessed by MR sialography (r= - 0.754, p<0.05). One patient stopped cevimeline at 4 weeks because of headache and nausea. There was no significant change in laboratory data. Cevimeline is safe and effective medicine for dry mouth in patients with SS, in particular, with less severe salivary gland destruction.
Ogawa
Noriyoshi
N
Division of Hematology & Immunology, Department of Internal Medicine, Kanazawa Medical University.
Shimoyama
Kumiko
K
Karasawa
Hiromi
H
Fukushima
Toshihiro
T
Masaki
Yasufumi
Y
Wano
Yuji
Y
Hirose
Yuko
Y
Sugai
Susumu
S
D005260:Female; D006801:Humans; D008875:Middle Aged; D018721:Muscarinic Agonists / Q000627:therapeutic use*; D011812:Quinuclidines / Q000627:therapeutic use*; D012859:Sjogren's Syndrome / Q000188:drug therapy*; D013876:Thiophenes / Q000627:therapeutic use*; D014987:Xerostomia / Q000188:drug therapy*
D018721:Muscarinic Agonists; D011812:Quinuclidines; D013876:Thiophenes; C059240:cevimeline